# Redirected Auto T Cells for Advanced Myeloma

> **NCT01352286** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **GENETIC:** Autologous Genetically modified T cells

## Key facts

- **NCT ID:** NCT01352286
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-13
- **Primary completion:** 2017-08-25
- **Final completion:** 2019-07-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01352286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01352286, "Redirected Auto T Cells for Advanced Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01352286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*